AU2002247946B2 - Process for the preparation of nanosized iron oxide by biomimetic route - Google Patents
Process for the preparation of nanosized iron oxide by biomimetic route Download PDFInfo
- Publication number
- AU2002247946B2 AU2002247946B2 AU2002247946A AU2002247946A AU2002247946B2 AU 2002247946 B2 AU2002247946 B2 AU 2002247946B2 AU 2002247946 A AU2002247946 A AU 2002247946A AU 2002247946 A AU2002247946 A AU 2002247946A AU 2002247946 B2 AU2002247946 B2 AU 2002247946B2
- Authority
- AU
- Australia
- Prior art keywords
- iron oxide
- preparation
- solution
- nanosized
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 title claims description 26
- 238000000034 method Methods 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 9
- 230000003592 biomimetic effect Effects 0.000 title description 7
- 239000000243 solution Substances 0.000 claims description 21
- 229920000642 polymer Polymers 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 239000008367 deionised water Substances 0.000 claims description 9
- 150000002505 iron Chemical class 0.000 claims description 8
- 239000012266 salt solution Substances 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 5
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 5
- 229910021538 borax Inorganic materials 0.000 claims description 5
- AJFXNBUVIBKWBT-UHFFFAOYSA-N disodium;boric acid;hydrogen borate Chemical compound [Na+].[Na+].OB(O)O.OB(O)O.OB(O)O.OB([O-])[O-] AJFXNBUVIBKWBT-UHFFFAOYSA-N 0.000 claims description 5
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 claims description 5
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 5
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 5
- 229910001448 ferrous ion Inorganic materials 0.000 claims description 4
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 3
- 229910001447 ferric ion Inorganic materials 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 229960002089 ferrous chloride Drugs 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 239000002245 particle Substances 0.000 description 29
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- 238000005054 agglomeration Methods 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 238000003491 array Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033558 biomineral tissue development Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001350 scanning transmission electron microscopy Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011554 ferrofluid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- -1 iron ion Chemical class 0.000 description 1
- 229910021506 iron(II) hydroxide Inorganic materials 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0063—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use in a non-magnetic matrix, e.g. granular solids
Landscapes
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Power Engineering (AREA)
- Radiology & Medical Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compounds Of Iron (AREA)
Description
WO 03/081612 PCT/IN02/00070 PROCESS FOR THE PREPARATION OF NANOSOZED IRON OXIDE BY BIOMIMETIC ROUTE Field of the invention The present invention relates to a process for the preparation ofnanosized iron oxide by biomimetic route. The present invention particularly relates to a biomimetic process for preparation of nanosized magnetite particles used for the enhancement of magnetic resonance imaging contrast. The nanosized magnetite, a form of iron oxide, is biodegradable, nontoxic and has size in the range of 4-20 nanometer. The particles, being super-paramagnetic in nature and exhibiting a narrow size distribution, arte useful generally in the fields of medical treatment and specifically of Magnetic Resonance Imaging.
Background of the invention Magnetic resonance imaging (MRI) is widely used for diagnostic imaging of the soft tissues and has been proven to be better to computed tomography for the detection of lever metastases. The screening and follow up of any kind of metastasis using contrast-enhanced MRI is an interesting tool for oncologists because ultrasound (US) is operator dependent and not always reproducible. Therefore, various contrast agents for an improved MR imaging have been developed by the pharmaceutical companies to serve the purpose.
Several metal chelates comprising of a highly magnetic cation Gd such as Gd- DTPA (Diethylene Triamine Pentaacetic Acid) are available for ready clinical use. These agents have been applied in enhancing the image contrast either as coating material in a therapeutic device or as directed agents for a specific organ. The only commercially available iron oxide for use in MRI contrast is ferumoxide, which has a supraparamagnetic crystalline core (nanosized magnetite) surrounded by dextra-coating. Being produced by conventional chemical method these magnetite particles suffer the limitations of the chemical synthesis route such as poor control over size and morphology. Thus, the supraparamagnetic behaviour of the particles ultimately deteriorates and makes them unsuitable for applications.
In a conventional method of production of nanosized magnetite particles developed by David and Welch. David and A.J.E. Welch, Trans. Faraday Soc. 52 (1956) 1642) ferrous sulphate solution is heated to 90'C and a solution of potassium hydroxide and potassium nitrate added drop-wise over a few minutes. The suspension was heated for minutes with continuous stirring followed by cooling, washing and drying leading to the formation of black precipitate of magnetite powder. It is mandatory to carry out the entire under an atmosphere of nitrogen.
In another known process by Schikorr G. Schikorr, Z. Electrochem 35 (1929) alkaline hydrolysis of ferrous sulphate solution is carried out to yield ferrous hydroxide followed by it's further oxidation at 100°C leading to the formation of magnetite powder along with evolution of hydrogen gas.
In another known process, reaction of ferrous/ferric solution under alkaline condition at 80°C under nitrogen atmosphere leads to the formation of magnetite particles (Regazzoni Urrutia Blesa M.A. and Maroto A.J.G. Inorg. Nucl.
Chem, 43 (1981) 1489).
In hitherto known processes the magnetite particles produced have poor crystallinity, a wide range of size distribution, random variation in morphology and magnetically induced agglomeration. The above limitations reduce the applicability of the magnetite particles in the field of medicine.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
Summary of the Invention In a preferred embodiment, the present invention provides a process for preparation of nanosized iron oxide by biomimetic route, which obviates the drawbacks as detailed above.
In another preferred embodiment, the present invention provides a biomimetic process for preparation of nanosized magnetic particles used for enhancement of magnetic resonance imaging contrast.
In one aspect, the present invention provides a process for preparation of nanosized iron oxide by biomimetic route which comprises: i) mixing polyvinyl alcohol of strength ranging between 0. 1-0.6% and disodium tetraborate solution of strength ranging between 01-0.6% in deionised water with continuous stirring; ii) mixing the above said reaction mixture with an iron salt solution of strength ranging between 0.01-0.02 M in deionised water under nitrogen atmosphere, at a pH in the range of 3-6 and stirring for about 20 minutes with a magnetic stirrer; iii) heating the above resultant solution at a temperature in the range of 40-60"C for a period of about 24 hours under nitrogen atmosphere to obtain an iron ion loaded cross linked polymer gel; iv) soaking the above said polymer gel for a period ranging from 2 to 4 hours into sodium hydroxide solution of strength ranging between 0.00-0.009M, at a temperature ranging between 40-50 °C; v) washing the above soaked polymer gel with de-ionized water to remove the sodium chloride salt and recovering the nanosized iron oxide particles from the soaked polymer gel.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
WO 03/081612 PCT/IN02/00070 In one embodiment of the invention, the polyvinyl alcohol and disodium tetraborate solution are taken in a volumetric ratio ranging between 9:1 to 12:1 In another embodiment of the invention, the reaction mixture obtained in step and the iron salt solution are taken in a volumetric ratio ranging from 2:1 to 5:1.
In an embodiment of the invention the iron salt solution used is a mixture of ferric chloride and ferrous chloride in de-ionized water.
Detailed description of the invention In nature, the synthesis of nano and micro sized inorganic particles is observed since the evaluation of life. The process is termed as bio-mineralization and it exhibits a high degree of control over the nucleation and growth of the synthesized particles, which perform different functions under different conditions and do not agglomerate. Our teeth, bones, shells, etc. are the products of biomineralization and nature carries out these in situ synthesis under the control of a biopolymeric matrix.
In the process of present invention in laboratory a method has been developed for in situ precipitation of nanosized magnetite particles in a pre-organized polymeric matrix made of a water-soluble polymer like polyvinyl alcohol at room temperature. The method produced magnetite particles in the size range of 5-10 nm having uniform morphology and orientation with supraparamagnetic behavior.
Under the optimum conditions of temperature, concentration, pH and a specific volumetric ratio, the underlying polymeric matrix provides a regularly arranged and uniformly distributed reaction as well as nucleation sites in the self assembled polymeric network formed as a result of gelation and cross-linking. The process involves a weak complexion (via dative bond formation) of ferrous/ferric ions (acceptor atom) with the active functional groups (donor atom) of the underlying polymer. An enhancement in the degree of saturation of ferrous/ferric ions locally at the complexion sites leads to the precipitation of nanosized magnetite particles under alkaline conditions at an optimum temperature.
Adsorption of the polymer at the surface of the precipitate limits the dimensions of particles in nanometer size range and the polymer matrix anisotropy induces an orientation during the particle growth.
By the process of the present invention, a single phase agglomeration free magnetite particles in size range of 5-10 nanometer and oriented in form of linear arrays are produced.
The novelty of the present route is the in situ synthesis of the magnetite particles in preorganized polymer matrix. The polymer matrix controls the particles shape and size and regulates the precipitation process. The inventive step of the present invention is the chelation WO 03/081612 PCT/IN02/00070 of ferrous ions by weak van der Wall bonds and hydrogen bonds present in cross-liked polymer matrix. The cross linking of the polymer provides a biopolymer like medium for mineralization which is characterized by regular arrangement of nano reactors and avoids agglomeration of the particles and induce precipitation under mild conditions of super saturation.
The following examples are given by way of illustration and should not be construed to limit the scope of the present invention.
Example 1 ml 0.5% polyvinyl alcophol was mixed with 15 ml of 0.013 M iron salt solution (prepared by dissolving ferric chloride and ferrous chloride salt in the deionized water in the ratio by weight of 3:2) in the volumetric ratio of 4:1 by continuous stirring using a magnetic stirrer. The pH of the solution was observed 3. The resulting solution was poured into a Petri dish and subjected to gel formation in an oven at 40 0 C maintaining nitrogen atmosphere for 24 hours. The thin dried light yellow film (gel) was soaked for 4 hours in 0.00625 M sodium hydroxide solution taken in a beaker and heated to 40 0 C following which color of the film changed from light yellow to black. Next, the black film was washed thoroughly by diionized water and again it was dried at 40 0 C in the same oven maintaining nitrogen atmosphere for 24 hours. Finally, the washed and dried sample was structurally characterized using X-ray diffraction, scanning electron microscopy and transmission electron microsocopy. The analysis of the results obtained confirmed the formation of single phase magnetite particles in the form of oriented and regularly arranged linear arrays having a low particle density showing agglomeration to certain extent and size in the range of 10-40nm.
Recovery of the iron oxide was close to 100%.
Example 2 60 ml of 0.5% polyvinyl alcohol solution was mixed with 6 ml of 0.5% disodium tetra borate solution in the volume ratio of 10:1 mixed by continuous stirring using a magnetic stirrer. Net, 15 ml of 0.013 M iron salt solution (prepared by dissolving ferric chloride and ferrous chloride salts in de-ionized in the ratio 3:2) was added in a volume ratio 4:1 by continuous stirring using a magnetic stirrer. The pH of the solution was observed to be 5. The resulting solution was poured into a Petri dish and was subjected to gel formation in an oven at 40°C maintaining nitrogen atmosphere. The dried film was soaked in 0.00625M sodium hydroxide take in a beaker heated to 40 0 C, for 4 hours following which, color of the film changed from light yellow to black. Next, the film was washed thoroughly with de-ionized water and dried in an oven at 60 0 C for 24 hours maintaining nitrogen atmosphere. The WO 03/081612 PCT/IN02/00070 washed and dried sample was structurally characterized by X-ray diffraction, scanning electron microscopy and transmission electron microscopy. The analysis of the results obtained linear arrays widely distributed throughout the matrix network being parallel to each other. The particle size in the case was observed to be decreased to a range of 10-20 r1n.
More number of arrays with increased particle density and almost without any agglomeration was observed in this case. The recovery rate of iron oxide was close to 100%.
Example 3 ml of 0.5% polyvinyl alcohol solution was mixed with 6 ml 0.5% disodium tetra borate solution with continuous stirring using magnetic stirrer at room temperature. The pH of the solution was observed -to be 5. To this, 15 ml of iron salt solution (prepared by dissolving ferric chloride and ferrous chloride salt in deionized water in the ratio 3:2) was added, again with continuous stirring and the resulting solution was poured into a Petri dish and kept in an oven for gel formation at 40 0 C under nitrogen atmosphere for 24 hours. Next, the dried light yellow gel was soaked for 4 hours in 0.00625 M sodium hydroxide solution taken in a beaker and heated to 40 0 C, following which color of the gel changes from light yellow to black. It was washed 4 to 5 times with de-ionized water and dried at 40 0 C in an oven under nitrogen atmosphere. The washed and dried film was structurally characterized by X-ray diffraction, scanning electron microscopy and transmission electron microscopy.
The analysis of data indicated the presence of single phase magnetite in the form of linearly oriented arrays, arranged regularly, parallel to each other widely distributed throughout the matrix with high particle density in the matrix nucleation sites. The particle size in this case ranged from 5-10 nm, had a high aspect ratio and were with no agglomeration. The recovery rate of iron oxide was close to 100%.
The main advantages of the present inventions are: 1. The invention provides a room temperature process for the preparation of nanosized magnetite particles suitable for application in magnetic resonance image contrast enhancement.
2. The invention leads to agglomeration free magnetite particles with uniform shape and size.
3. The size distribution of the particles is very narrow.
4. The produced particles being super-paramagnetic in nature can be used in other applications also involving ferro fluids.
Claims (6)
- 2. A process as claimed in claim 1 wherein the polyvinyl alcohol and disodium tetraborate solution are taken in a volumetric ratio ranging between 9:1 to 12:1.
- 3. A process as claimed in claim 1 or 2 wherein the reaction mixture obtained in step and the iron salt solution are taken in a volumetric ratio ranging from 2:1 to 5:1.
- 4. A process as claimed in any one of claims 1-3 wherein the iron salt solution used is a mixture of ferric chloride and ferrous chloride in de-ionized water.
- 5. A process as claimed in any one of claims 1-4 wherein the polymer gel is in the form of a polymer matrix and controls the size and shape of the iron oxide formation.
- 6. A process as claimed in claim 5 wherein the ferric and ferrous ions are chelated by weak van der Wall bonds and hydrogen bonds present in the polymer matrix.
- 7. A process for preparation of nanosized iron oxide by biomimetric route, substantially as hereinbefore described with reference to any one of Examples 1-3. Dated this fourteenth day of June 2007 Council of Scientific and Industrial Research Patent Attorneys for the Applicant: F B RICE CO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2002/000070 WO2003081612A1 (en) | 2002-03-26 | 2002-03-26 | Process for the preparation of nanosozed iron oxide by biomimetic route |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002247946A1 AU2002247946A1 (en) | 2003-10-08 |
| AU2002247946B2 true AU2002247946B2 (en) | 2007-10-04 |
Family
ID=28053428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002247946A Ceased AU2002247946B2 (en) | 2002-03-26 | 2002-03-26 | Process for the preparation of nanosized iron oxide by biomimetic route |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR100626096B1 (en) |
| AU (1) | AU2002247946B2 (en) |
| GB (1) | GB2403215B (en) |
| WO (1) | WO2003081612A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070044817A (en) * | 2004-06-27 | 2007-04-30 | 조마 케미칼 에이에스 | Method for producing iron oxide nanoparticles |
| IT1397612B1 (en) * | 2009-12-15 | 2013-01-18 | Colorobbia Italia Spa | MAGNETITE IN NANOPARTICELLAR FORM |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0600529A2 (en) * | 1992-12-02 | 1994-06-08 | NanoSystems L.L.C. | Preparation and magnetic properties of very small magnetite-dextran particles |
-
2002
- 2002-03-26 WO PCT/IN2002/000070 patent/WO2003081612A1/en not_active Ceased
- 2002-03-26 GB GB0421445A patent/GB2403215B/en not_active Expired - Fee Related
- 2002-03-26 KR KR1020047015467A patent/KR100626096B1/en not_active Expired - Fee Related
- 2002-03-26 AU AU2002247946A patent/AU2002247946B2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0600529A2 (en) * | 1992-12-02 | 1994-06-08 | NanoSystems L.L.C. | Preparation and magnetic properties of very small magnetite-dextran particles |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040111453A (en) | 2004-12-31 |
| KR100626096B1 (en) | 2006-09-21 |
| WO2003081612A1 (en) | 2003-10-02 |
| AU2002247946A1 (en) | 2003-10-08 |
| GB2403215B (en) | 2005-10-12 |
| GB2403215A (en) | 2004-12-29 |
| GB0421445D0 (en) | 2004-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Daou et al. | Coupling agent effect on magnetic properties of functionalized magnetite-based nanoparticles | |
| Yuen et al. | The interplay of catechol ligands with nanoparticulate iron oxides | |
| Liu et al. | Water-dispersible magnetic carbon nanotubes as T2-weighted MRI contrast agents | |
| Vinslava et al. | Molecules at the quantum–classical nanoparticle interface: giant Mn70 single-molecule magnets of∼ 4 nm diameter | |
| JP5569837B2 (en) | Method for producing surface-coated inorganic particles | |
| US6800271B2 (en) | Process for the preparation of nanosized iron oxide by biomimetic route | |
| Chiu et al. | Enhanced Raman sensitivity and magnetic separation for urolithiasis detection using phosphonic acid-terminated Fe 3 O 4 nanoclusters | |
| Lassenberger et al. | Biocompatible glyconanoparticles by grafting sophorolipid monolayers on monodispersed iron oxide nanoparticles | |
| TW200914049A (en) | One kind of nanometer-scaled magnetic hydroxyapatite particle and its manufacturing method | |
| CN117797282B (en) | Polyaspartic acid grafted dopamine and ethanolamine polymer chelated iron oxide nanoparticles and their radionuclide labeling | |
| Pazik et al. | Energy conversion and biocompatibility of surface functionalized magnetite nanoparticles with phosphonic moieties | |
| Khosroshahi et al. | Characterization and Cellular Fluorescence Microscopy of Superparamagnetic Nanoparticles Functionalized with Third Generation Nano-molecular Dendrimers: In-vitro Cytotoxicity and Uptake study. J Nanomater Mol Nanotechnol 5: 3 | |
| AU2002247946B2 (en) | Process for the preparation of nanosized iron oxide by biomimetic route | |
| Caspani et al. | Anisotropic porous iron-based nanoparticles through two-step hydrothermal and hydrogen-based reduction: Enhanced magnetic performance for potential biomedical applications | |
| AU2019203072B2 (en) | A multimodal pet/mri contrast agent and a process for the synthesis thereof | |
| CN109516503A (en) | A kind of preparation method of high stability water-base nano magnetic fluid | |
| Carron et al. | Potential theranostic and multimodal iron oxide nanoparticles decorated with rhenium–bipyridine and–phenanthroline complexes | |
| Katkova et al. | Water-soluble 15-metallacrown-5 complexes: Molecular structures and properties | |
| Dietrich et al. | Electron Beam-Assisted Synthesis of Superparamagnetic Iron Oxide Nanoparticles: Reaction Kinetics and Structural–Magnetic Properties | |
| CN102430130B (en) | Medical modified glucan coated magnetic nanometer particle composite material and preparation method thereof | |
| Li et al. | Application of Gd (III) complexes for magnetic resonance imaging and the improvement of relaxivities via nanocrystallization | |
| CN113058044B (en) | Dynamic organic gadolinium nanoparticles and application thereof | |
| Chen et al. | Localized assembly-based laponite for high dual-mode activity and biocompatibility | |
| CN112516334B (en) | A kind of EDTMP modified ferric oxide nanoparticles and preparation method and application thereof | |
| KR101136190B1 (en) | Magnetic nano-particles coated by biocompatible polymer and method for manufacturing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO PROCESS FOR THE PREPARATION OF NANOSIZED IRON OXIDE BY BIOMIMETIC ROUTE. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |